Business
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in
About this update from Lakefront Biotherapeutics
[{"type":"image","alt":"Galapagos NV","displaySize":"","headline":null,"caption":"Galapagos NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n2iAy9u_uXZxYevnIzv00A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9","width":300,"height":55}},"lazy":false},{"type":"text","content":"Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments","length":127,"tagName":"p"},{"type":"text","content":"Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions","length":200,"tagName":"p"},{"type":"text","content":"Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in April 2025","length":181,"tagName":"p"},{"type":"text","content":"Mr. Jérôme Contamine, formerly Lead Non-Executive Director, has been appointed Chair of the Board of Directors of Galapagos, replacing Dr. Paul Stoffels","length":152,"tagName":"p"},{"type":"text","content":"Mechelen, Belgium; May 13, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today provides a strategic update on the proposed separation, executive leadership transition and changes to its Board of Directors. ","length":390,"tagName":"p"},{"type":"text","content":"On January 8, 2025, Galapagos announced its intention to separate into two publicly traded entities with Galapagos to advance novel cell therapies and SpinCo, a new biotechnology company focused on building a pipeline of innovative medicines through transformational transactions. This planned separation, subject to shareholder approval and other customary conditions, was expected by mid-2025.","length":395,"tagName":"p"},{"type":"text","content":"Since this initial announcement, the Company has made significant progress...